batefenterol

Small moleculeexperimental

Clinical trial activity

13 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
6
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2005 (NCT00887406)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12
Mol. weight
740.26 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • batefenterol
  • batefenterol
  • batefenterol
  • batefenterol
  • gsk961081
  • gsk961081
  • gsk961081
  • gsk961081a
  • gsk961081a
  • td-5959
  • td-5959

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02663089Phase 1Feb 8, 2016GlaxoSmithKline, Hammersmith Medicines Research
NCT02666287Phase 1Jan 27, 2016GlaxoSmithKline, Hammersmith Medicines Research
NCT02573870Phase 2Dec 1, 2015GlaxoSmithKline
NCT02570165Phase 2Nov 1, 2015GlaxoSmithKline
NCT02577926Phase 3Oct 1, 2015Novartis, RWTH Aachen University
NCT02064504Phase 1Feb 19, 2014GlaxoSmithKline
NCT01449799Phase 1Jul 1, 2011GlaxoSmithKline
NCT01319019Phase 2Dec 1, 2010GlaxoSmithKline
NCT00674817Phase 2Apr 1, 2008GlaxoSmithKline
NCT00687700Phase 1Mar 1, 2008GlaxoSmithKline
NCT00550225Phase 1Nov 1, 2007GlaxoSmithKline
NCT00478738Phase 2Jun 1, 2007GlaxoSmithKline
NCT00887406Phase 1Nov 1, 2005GlaxoSmithKline
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit121222005
Hammersmith Medicines ResearchFor profit2012016
NovartisFor profit1012015
RWTH Aachen UniversityAcademic/Hospital1112015
4 organizations
Page 1 / 1